Cardio Diagnostics Holdings Inc. announced that the Japan Patent Office has issued a patent for a set of biomarkers within the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” is Japanese Patent No. 7672192.
This patent is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names the company’s founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., as inventors. It strengthens the company's global IP strategy, adding to existing patents in the United States, Europe, Australia, India, and China.
The Japanese patent protects the company’s novel methods and compositions for detecting cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through machine learning algorithms. This issuance underscores the global applicability of Cardio Diagnostics' pioneering approach to heart disease prevention.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.